HC Wainwright & Co. Upgrades Addex Therapeutics to Buy, Announces $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has upgraded Addex Therapeutics (NASDAQ:ADXN) from Neutral to Buy, with a new price target of $30.
July 31, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has upgraded Addex Therapeutics from Neutral to Buy, setting a new price target of $30. This upgrade could positively impact the stock price in the short term.
The upgrade from Neutral to Buy by a reputable analyst firm like HC Wainwright & Co. and the announcement of a $30 price target are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100